Repositorio Digital de la UPF
Publicación
Artículo científico (JournalArticle)
Macrophage and neutrophil heterogeneity at single-cell spatial resolution in human inflammatory bowel disease
Ulcerative colitis and Crohn's disease are chronic inflammatory intestinal diseases with perplexing heterogeneity in disease manifestation and response to treatment. While the molecular basis for this heterogeneity remains uncharacterized, single-cell technologies allow us to explore the transcriptional states within tissues at an unprecedented resolution which could further understanding of these complex diseases. Here, we apply single-cell RNA-sequencing to human inflamed intestine and show that the largest differences among patients are present within the myeloid compartment including macrophages and neutrophils. Using spatial transcriptomics in human tissue at single-cell resolution (CosMx Spatial Molecular Imaging) we spatially localize each of the macrophage and neutrophil subsets identified by single-cell RNA-sequencing and unravel further macrophage diversity based on their tissue localization. Finally, single-cell RNA-sequencing combined with single-cell spatial analysis reveals a strong communication network involving macrophages and inflammatory fibroblasts. Our data sheds light on the cellular complexity of these diseases and points towards the myeloid and stromal compartments as important cellular subsets for understanding patient-to-patient heterogeneity., This work was funded by grant PID2021-123918OB-I00 from MCIN/AEI/ 10.13039/501100011033 and co-funded by “FEDER A way to make Europe”. AM-C, VG and ID were funded by grant Grant #2008-04050 from The Leona and Harry B. Helmsley Charitable Trust. EM-A is funded by grant RH042155 (RTI2018-096946-B-I00) from Ministerio de Ciencia e Innovacion. IA-T is funded by grant 831434-2 (CE_IMI2-2018-14 call). HH received support for the project PID2020-115439GB-I00- funded by MCIN/AEI/10.13039/501100011033. This publication is part of a project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831434. This project also has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 848028.